Affimed (NASDAQ:AFMD) Short Interest Update

Affimed (NASDAQ:AFMD) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 718,200 shares, a decline of 9.4% from the August 15th total of 792,600 shares. Currently, 5.5% of the company’s stock are sold short. Based on an average trading volume of 181,600 shares, the short-interest ratio is presently 4.0 days.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in AFMD. BNP Paribas Financial Markets increased its holdings in shares of Affimed by 39.9% during the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after purchasing an additional 163,162 shares during the period. Vestal Point Capital LP acquired a new stake in Affimed during the fourth quarter worth approximately $341,000. Finally, Choreo LLC bought a new position in Affimed during the 2nd quarter worth $54,000. Institutional investors own 30.82% of the company’s stock.

Affimed Price Performance

Shares of AFMD stock opened at $4.07 on Wednesday. Affimed has a 12-month low of $2.23 and a 12-month high of $8.95. The firm has a 50 day moving average price of $4.48 and a two-hundred day moving average price of $5.16. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.71 and a current ratio of 2.71.

Analyst Ratings Changes

A number of brokerages have commented on AFMD. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Affimed in a research note on Friday, September 6th. Laidlaw lifted their price target on Affimed from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research note on Monday, September 9th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat.com, Affimed has an average rating of “Moderate Buy” and an average target price of $32.50.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.